Cheshire, UK--(Marketwire - December 3, 2007) -
Protherics PLC
Total Voting Rights and Share Capital
London, UK; Brentwood, TN; 3 December 2007 - In conformity with the Transparency
Directive, Protherics PLC ("Protherics"), the international biopharmaceutical
company focused on critical care and cancer, notifies the market of the
following:
Protherics' issued share capital consists of 339,950,033 ordinary shares with a
nominal value of 2 pence each, with voting rights. Protherics does not hold any
ordinary shares in Treasury. Therefore, the total number of voting rights in
Protherics is 339,950,033.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, Protherics under the Financial
Services Authority's Disclosure and Transparency Rules.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange